Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company ...

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across ...

Your home environment can have a significant impact on your mental health, especially during the colder months. Here’s how ...

Night after night, many people find themselves jolting awake at a strangely precise time, staring at the clock and wondering ...

GLP-1 weight loss drugs such as Ozempic and Wegovy have taken the world by storm. But some side effects, from the accepted - ...

December 26, 2025 A newly released clinical review is drawing attention within medical and regulatory communities by consolidating available evidence on the side-effect profile of a widely prescribed ...

An analysis of major depressive disorder, covering diagnostic criteria, prevalence statistics across demographics, and ...

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to Reached written alignment with FDA on inclusion of =3 months of safety data from ASPIRE trial evaluating TSHA-102 (N=3 ...

In 2025, EE World produced twenty-four EE Training Days webinars designed to educate engineers on practical design challenges ...

Dr Leddy called for an urgent public meeting on air pollution and called for the council to give priority to electric buses along Lewes Road, reduce idling from waiting traffic and introduce a clean ...

A vanishingly rare genetic glitch in a single enzyme can erase a newborn’s brain cells in a matter of weeks, leaving doctors ...

Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL ™, a patented ...